PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.36%
Cash & equivalents growing 2.36% while RVPH's declined -48.40%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
2.36%
Below half of RVPH's -48.40%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.66%
Other current assets growth 50-75% of RVPH's -29.27%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
1.99%
Below half of RVPH's -46.41%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.06%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.24%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Below half of RVPH's -40.34%. Michael Burry sees a potential red flag for stagnation or capital shortage.
22.15%
Less than half of RVPH's -17.95%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
20.63%
Less than half of RVPH's -3.78%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.37%
Less than half of RVPH's -57.14%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
3.44%
Less than half of RVPH's -5.04%. David Dodd sees far fewer liability expansions relative to competitor.
6.90%
Similar yoy changes to RVPH's 6.81%. Walter Schloss sees parallel capital-raising strategies.
-3.28%
0.5-0.75x RVPH's -5.54%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to RVPH's zero value, indicating worse performance.
-0.05%
Below half RVPH's -348.91%. Michael Burry sees potential underperformance in building shareholder capital.
1.71%
Below half RVPH's -40.34%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.63%
Higher Total Investments Growth compared to RVPH's zero value, indicating better performance.
-6.71%
Less than half of RVPH's -37.50%. David Dodd sees less overall debt expansion vs. competitor.
-2.57%
Less than half of RVPH's 48.71%. David Dodd sees better deleveraging or stronger cash buildup than competitor.